Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
22.88
-0.77 (-3.26%)
At close: Mar 24, 2026, 4:00 PM EDT
22.70
-0.18 (-0.79%)
Pre-market: Mar 25, 2026, 5:12 AM EDT
Mineralys Therapeutics Employees
Mineralys Therapeutics had 76 employees as of December 31, 2025. The number of employees increased by 25 or 49.02% compared to the previous year.
Employees
76
Change (1Y)
25
Growth (1Y)
49.02%
Revenue / Employee
n/a
Profits / Employee
-$2,034,882
Market Cap
1.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 25 | 49.02% |
| Dec 31, 2024 | 51 | 23 | 82.14% |
| Dec 31, 2023 | 28 | 16 | 133.33% |
| Dec 31, 2022 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Sarepta Therapeutics | 835 |
| Galapagos NV | 558 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
| AnaptysBio | 104 |
| Tyra Biosciences | 87 |
MLYS News
- 23 hours ago - Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - GlobeNewsWire
- 12 days ago - Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 15 days ago - Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results - GlobeNewsWire
- 15 days ago - Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 - GlobeNewsWire
- 26 days ago - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 - GlobeNewsWire
- 3 months ago - Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026 - Seeking Alpha